MX2014008375A - Formulaciones pedriaticas de supspension oral de amoxicilina y clauvulanato de potasio y metodo para su uso. - Google Patents

Formulaciones pedriaticas de supspension oral de amoxicilina y clauvulanato de potasio y metodo para su uso.

Info

Publication number
MX2014008375A
MX2014008375A MX2014008375A MX2014008375A MX2014008375A MX 2014008375 A MX2014008375 A MX 2014008375A MX 2014008375 A MX2014008375 A MX 2014008375A MX 2014008375 A MX2014008375 A MX 2014008375A MX 2014008375 A MX2014008375 A MX 2014008375A
Authority
MX
Mexico
Prior art keywords
amoxicillin
oral suspension
same
clavulanate potassium
pediatric oral
Prior art date
Application number
MX2014008375A
Other languages
English (en)
Inventor
Spector Michael
Hoberman Alejandro
Original Assignee
Spector Michael
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spector Michael filed Critical Spector Michael
Publication of MX2014008375A publication Critical patent/MX2014008375A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se refiere a una composición de suspensión oral pediátrica que contiene amoxicilina y clavulanato de potasio donde el clavulanato de potasio se encuentra presente en una cantidad igual o menor que aproximadamente 21.5 mg/5 mL y un método para tratar infecciones bacterianas mediante la administración de entre aproximadamente uno y aproximadamente catorce días de dosificación de la composición.
MX2014008375A 2012-01-10 2013-01-10 Formulaciones pedriaticas de supspension oral de amoxicilina y clauvulanato de potasio y metodo para su uso. MX2014008375A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261585234P 2012-01-10 2012-01-10
PCT/US2013/021072 WO2013106601A1 (en) 2012-01-10 2013-01-10 Pediatric oral suspension formulations of amoxicillin and clavulanate potassium and method for using same

Publications (1)

Publication Number Publication Date
MX2014008375A true MX2014008375A (es) 2017-07-27

Family

ID=48781913

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014008375A MX2014008375A (es) 2012-01-10 2013-01-10 Formulaciones pedriaticas de supspension oral de amoxicilina y clauvulanato de potasio y metodo para su uso.

Country Status (6)

Country Link
US (1) US9987257B2 (es)
EP (1) EP2802327A1 (es)
KR (1) KR20140117523A (es)
BR (1) BR112014016850A8 (es)
MX (1) MX2014008375A (es)
WO (1) WO2013106601A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013173808A2 (en) * 2012-05-17 2013-11-21 Michael Spector Methods for use of lower dose compositions of amoxicillin and clavulanate potassium and devices for use
WO2013173803A2 (en) * 2012-05-17 2013-11-21 Michael Spector Formulations of amoxicillin and clavulanate potassium and methods for using same
CN114533852A (zh) * 2022-02-25 2022-05-27 四川恒通动保生物科技有限公司 一种复方阿莫西林硫酸黏菌素混悬注射液及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ2028A1 (fr) * 1995-05-03 2002-10-23 Smithkline Beecham Plc Médicaments destinés au traitement d'infections bactériennes en pédiatrie.
EP1147771A1 (en) * 1995-09-07 2001-10-24 Smithkline Beecham Corporation Pharmaceutical formulation containing amoxycillin and clavulanate
SI21221A (sl) * 2002-06-21 2003-12-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Hitro razpadljive tablete
EP1596841B1 (en) * 2003-02-21 2008-10-08 LEK Pharmaceuticals D.D. Therapeutic system comprising amoxicillin and clavulanic acid
GB0313913D0 (en) 2003-06-16 2003-07-23 Beecham Pharm Pte Ltd New use
RU2343931C2 (ru) * 2003-06-16 2009-01-20 Глаксо Груп Лимитед Фармацевтические препараты, содержащие амоксициллин и клавуланат
CN1968682A (zh) * 2004-06-18 2007-05-23 株式会社柳韩洋行 包含表面改性的碳酸氢钠的阿莫西林和/或克拉维酸口服分散片组合物
CA2598668A1 (en) * 2005-02-25 2006-09-08 Mutual Pharmaceutical Company, Inc. Dosage forms of antibiotics and combinations of antibiotics and symptomatic relief agents

Also Published As

Publication number Publication date
EP2802327A1 (en) 2014-11-19
BR112014016850A2 (pt) 2017-06-13
BR112014016850A8 (pt) 2017-07-04
KR20140117523A (ko) 2014-10-07
WO2013106601A1 (en) 2013-07-18
US9987257B2 (en) 2018-06-05
US20160339002A1 (en) 2016-11-24

Similar Documents

Publication Publication Date Title
MX2019012979A (es) Composiciones para el cuidado bucal.
MX2019007187A (es) Composiciones para el cuidado bucal.
WO2017042607A3 (en) Compositions comprising meloxicam-cyclodextrin inclusion complexes and methods of treating acute pain
MX2015007556A (es) Derivados de manosa para tratar infecciones bacterianas.
PH12015501609A1 (en) Phenicol antibacterials
EP3904502A3 (en) Compositions and methods
UA109220C2 (uk) Похідні (4-фенілімідазол-2-іл)етиламіну як модулятори натрієвих каналів
EA201101192A1 (ru) Фармацевтическая композиция, включающая производные глюкопиранозилдифенилметана, фармацевтическая дозированная форма, содержащая указанные производные, способ их получения и применения для улучшения гликемического контроля у пациентов
MX2009010977A (es) Metodos de administracion de tetrahidrobiopterina, composiciones asociadas y metodos de medicion.
NZ744567A (en) Treatment of cancers using pi3 kinase isoform modulators
MX338515B (es) Derivados de tetrahidroquinolina utiles como inhibidores de bromodominio.
MX2013011086A (es) (aralquilamino y heteroarilalquilamino alfa-sustituidos)pirimidini lo y 1,3,5-triazinilbenzimidazoles, composiciones farmacéuticas que los contienen, y estos compuestos para su uso en el tratamiento de enfermedades proliferativas.
MX2018015132A (es) Composiciones para el cuidado bucal.
MX2021011982A (es) Metodos y composiciones para modular la microbiota intestinal y para manejar el peso.
SG10201900541QA (en) Derivatives of xanthone compounds
PH12018500378A1 (en) Novel annelated phenoxyacetamides
EP2590978A4 (en) CARBAPENEM ANTIBACTERIA WITH GRAM NEGATIVE ACTIVITY
MX368635B (es) Compuestos tricíclicos de piperidina.
MX2015000179A (es) Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.
MX2014008375A (es) Formulaciones pedriaticas de supspension oral de amoxicilina y clauvulanato de potasio y metodo para su uso.
MX2019007361A (es) Composiciones para el cuidado bucal.
WO2018062876A3 (ko) 통증이 경감되는 골관절염 치료용 키트
WO2012177075A3 (ko) 항생제 및 라이소포스파티딜콜린을 포함하는 면역 증강 또는 세균성 감염 질환 치료용 조성물
IN2015DN02109A (es)
WO2014145713A3 (en) Aminoglycoside antibiotics with reduced ototoxicity